| Bioactivity | EGFR/CDK2-IN-3 (compound 4b) is a dual inhibitor of EGFR and CDK-2 with IC50s of 71.7 and 113.7 nM, respectively. EGFR/CDK2-IN-3 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-3 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC50 of 3.16 μM[1]. |
| Target | IC50: 71.7 (EGFR), 113.7 nM (CDK-2) |
| Name | EGFR/CDK2-IN-3 |
| Formula | C30H20N6OS |
| Molar Mass | 512.58 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Salem M E, et al. Synthesis and Anti-Breast Cancer Potency of Mono-and Bis-(pyrazolyl [1, 2, 4] triazolo [3, 4-b][1, 3, 4] thiadiazine) Derivatives as EGFR/CDK-2 Target Inhibitors[J]. ACS Omega, 2023.. . . |